By facilitating exocytosis of granzyme A, EBAG9 silencing may compensate for a loss in therapeutic index, which may accompany engineering efforts aimed at mitigating on-target/off-tumor effects through reduction of CAR-antigen affinity. The gene discussed is EBAG9; the disease is neoplasm.